Magle Chemoswed establishes a manufacturing agreement with Oncopeptides

15 September 2021 - 13:50

Magle Chemoswed announces that it has entered into a long-term manufacturing agreement with Oncopeptides, a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases. The agreement comprises commercial manufacturing of the active pharmaceutical substance melflufen HCl (INN melphalan flufenamide) and the intermediate amino dipeptide. Melflufen, is a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly releases alkylating agents inside cancer cells.
The collaboration between Magle Chemoswed and Oncopeptides marks an important step for Magle Chemoswed as a full-service provider, supporting customers to fulfil their needs from early product development to commercialization. 
“We are proud that Oncopeptides has chosen Magle Chemoswed as the commercial manufacturer for this exciting product”, says Fredrik Andersson, COO of Magle Chemoswed. “It has been a fruitful collaboration during the development stages, and we look forward to continue working with Oncopeptides to support their success.”
“We are very happy to extend our successful relationship going forward”, says Fredrik Lehmann, Head of Research and CMC at Oncopeptides. “Magle Chemoswed has been a great support during development for many years and we believe they are the ideal partner when we are upgrading our commercial manufacturing.”

Provided by: MFN
Nasdaq First North GM (Sweden)
Magle Chemoswed Holding AB
Magle Chemoswed Holding AB is a contract development and manufacturing organization that serves companies in the pharmaceutical and medical device industry on a contract basis. It provides comprehensive services from product development through product manufacturing. The company's products portfolio includes Warfarin sodium, Melperone hydrochloride, Isradipine, Amantadine sulfate, and Benserazide...
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More